Treatments for ocular surface disorders
AssigneeGlaukos Corporation
InventorsShawn A. Scranton, Colin Richard Green, Brian Levy
Life of this patent
Estimating the term…
Abstract
The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.
Claims20
A method for treating a subject for a non-healing ocular surface defect, comprising administering to the eye of the subject a therapeutically effective amount of a composition comprising a connexin 43 modulator, wherein the connexin 43 modulator is lufepirsen (SEQ ID NO:
- 1) and the composition is administered at a dose of about 0.006 wt. % lufepirsen or 0.06 wt. % lufepirsen at least once on day 1, at least once on day 2, and at least once on about day 14.
A method for treating a subject for a persistent corneal epithelial defect, comprising administering to the eye of the subject a composition comprising about 0.06% or about 0.006% lufepirsen on day 1, on day 2, and on about day 14.
A pharmaceutical composition comprising about 0.6 or 0.06 mg/mL lufepirsen, about 226.9 mg/mL poloxamer 407, about 0.99 mg/mL sodium phosphate dibasic heptahydrate and about 0.25 mg/mL potassium phosphate, monobasic.
Dependencies are inferred from the claim text.